aibioFractyl cuts about 45% of staff and drops Rejuva gene therapy to fund Revita filing
Tickers GUTS
The company expects quarterly cash burn to fall by about half, to roughly $8 million, and says its cash lasts into the second quarter of 2027.
Key facts
- Company
- Fractyl Health, Inc. (NASDAQ: GUTS)
- News type
- Distress
- Primary source
- Fractyl Health (press release via BiopharmaWatch)
Fractyl Health said on October 22, 2026, that it will cut about 45% of its workforce and stop internal development of Rejuva, its gene therapy platform, to focus on Revita, a one-time endoscopic procedure meant to help people keep weight off after they stop GLP-1 drugs.
The Burlington, Massachusetts company expects the cuts to be substantially complete by November 2026. It said quarterly operating cash burn should fall about 50%, to roughly $8 million, by the end of the second quarter of 2027, and that existing cash will fund operations into the second quarter of 2027.
The details
Fractyl is seeking strategic alternatives for Rejuva and said there is no assurance that a transaction will result. Rejuva's lead candidate, RJVA-001, is a one-time AAV gene therapy for type 2 diabetes that had received authorization in the Netherlands for a first-in-human phase 1/2 trial, announced in May.
Co-founder Jay Caplan will retire from his executive roles effective October 30, 2026, and stay on as a senior adviser, the company said.
"We expect the capital we have today to be sufficient to fund our planned De Novo submission," said Harith Rajagopalan, co-founder and CEO, in the release.
The plan keeps Revita's timeline. Fractyl still expects to file a De Novo request with FDA in late fourth quarter 2026, report 12-month registrational data in the first quarter of 2027 and, if authorized, launch in the U.S. in early 2028.
Context
The restructuring came six days after Fractyl reported that the REMAIN-1 registrational cohort met its six-month co-primary endpoint. In 308 patients who lost at least 15% of body weight on tirzepatide and then stopped, Revita patients regained 5.1% of body weight against 8.2% for sham (p=0.0023). Shares fell sharply that day, according to BiopharmaWatch market data.
Fractyl had been trimming spending all year. It reported $63.2 million in cash at March 31, down from $81.5 million at the end of 2025, with first-quarter R&D of $15.6 million. In May it guided to a cash runway into early 2027. In June it hired Mike Zumdahl, a former Novo Nordisk and Inari Medical market access executive, to lead market access and commercial strategy.
What it means for investors
By the company's own guidance, the cuts add about one quarter of runway, from early 2027 to the second quarter of 2027. That covers the De Novo filing and the 12-month data. It does not cover an FDA decision, which the company targets for late 2027, or a launch in 2028.
That gap means Fractyl will likely need new money, a partner or both before Revita can earn revenue. Its 12-month data arrive in the first quarter of 2027. A raise after positive 12-month data would probably come on better terms than one before, which makes the first-quarter readout the next swing point.
Dropping Rejuva removes the company's second shot. Fractyl is now a single-product company whose value rides on one regulatory filing and one remaining co-primary endpoint: whether more than 50% of Revita patients keep at least 5% weight loss at 12 months, measured against an FDA-mandated performance goal.
What to watch
Workforce cuts finish by November 2026. The De Novo submission is planned for late fourth quarter 2026 and 12-month data for the first quarter of 2027. A Category III CPT code for the procedure takes effect on January 1, 2027.